MedPath
FDA Approval

NEOSTIGMINE METHYLSULFATE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Eugia US LLC
DUNS: 968961354
Effective Date
November 3, 2023
Labeling Type
Human Prescription Drug Label
Neostigmine(0.5 mg in 1 mL)

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Apitoria Pharma Private Limited

Eugia US LLC

918917662

Eugia Pharma Specialities Limited

Eugia US LLC

650498244

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

NEOSTIGMINE METHYLSULFATE

Product Details

NDC Product Code
55150-348
Application Number
ANDA213244
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
March 2, 2023
PHENOLInactive
Code: 339NCG44TVClass: IACT
Code: 98IMH7M386Class: ACTIBQuantity: 0.5 mg in 1 mL
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9BClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT

NEOSTIGMINE METHYLSULFATE

Product Details

NDC Product Code
55150-349
Application Number
ANDA213244
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
March 2, 2023
PHENOLInactive
Code: 339NCG44TVClass: IACT
Code: 98IMH7M386Class: ACTIBQuantity: 1 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9BClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
© Copyright 2025. All Rights Reserved by MedPath